unknown
Stage
About
Ermium Therapeutics was a biotech company developing functionally selective immunomodulators targeting CXCR4 for autoimmune disease indications, particularly interferonopathies including systemic lupus erythematosus (SLE). The company ceased operations in 2024.
Explore Ermium Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.